Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...

Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association. The rise in kidney disease rates is a ...

DALLAS, March 24, 2025 — Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global ...

"Kidney disease is a powerful risk predictor, and treating it is a way to reduce morbidity and mortality of cardiovascular disease," said Janani Rangaswami, M.D., FAHA, American Heart Association ...